US Patent 11,278,601: Scope, Claims, Expiration, and Pompe Disease Patent Landscape

US Patent No. 11,278,601 protects the use of a highly specified CHO-cell-produced recombinant human acid alpha-glucosidase, or rhGAA, together with oral miglustat for treating Pompe disease. Its strongest protection is directed to the combined therapeutic regimen, the enzyme's glycan and mannose-6-phosphate profile, and kits containing both treatment components. The patent does not broadly cover every rhGAA-plus-miglustat treatment. Infringement depends on satisfying multiple biochemical, manufacturing, dosage, and administration limitations.

What does US Patent 11,278,601 protect?

US 11,278,601 is a combination-treatment and kit patent. The independent claims require all of the following:

Required limitation	Scope under claim 1 or claim 10
Disease	Pompe disease
Small-molecule component	Miglustat
Enzyme component	Recombinant human acid alpha-glucosidase
Administration route	Miglustat orally; rhGAA intravenously
Miglustat dose	About 260 mg or about 130 mg
rhGAA dose	About 5 mg/kg to about 20 mg/kg
Host cell	Chinese hamster ovary, or CHO, cells
Glycosylation sites	Positions corresponding to N84, N177, N334, N414, N596, N826, and N869 of SEQ ID NO: 5
Complex N-glycans	40% to 60% of total N-glycans
Key targeting feature	At least 50% of rhGAA molecules have a bis-mannose-6-phosphate unit at N84

The patent therefore protects a defined product-and-regimen combination rather than a general concept of enzyme replacement therapy enhanced by a pharmacological chaperone.

The patent is particularly relevant to the cipaglucosidase alfa and miglustat regimen commercialized as Pombiliti and Opfolda. The patent itself must be read independently from the product labels because claim scope depends on the specified glycan distribution, site-specific phosphorylation, dose, timing, and manufacturing origin.[1]

How broad is independent claim 1?

Claim 1 is a method-of-treatment claim with unusually dense limitations. A competing product or regimen would need to meet each material limitation, either literally or potentially under the doctrine of equivalents.

The claim reaches a patient treatment only when:

The patient has Pompe disease.
Miglustat is administered orally.
The rhGAA composition is administered intravenously.
The doses fall within the stated ranges.
The enzyme is produced in CHO cells.
The enzyme has the seven specified potential N-glycosylation sites.
Complex N-glycans account for 40% to 60% of the N-glycans.
At least half of the rhGAA molecules contain a bis-M6P unit at N84.

The most commercially important limitations are the CHO-cell production requirement and the site-specific glycan profile. Those limitations can narrow infringement substantially because glycan occupancy and phosphorylation are product attributes that may vary by cell line, clone, culture conditions, purification process, and analytical method.

A biosimilar or follow-on enzyme could avoid literal infringement if its rhGAA is made in a different host cell, has a different glycan distribution, lacks the claimed N84 bis-M6P threshold, or falls outside the claimed complex-glycan range. A different manufacturing host would not automatically avoid every related patent in the broader family, but it would be significant for this patent's asserted claims.

What do dependent claims 2 through 9 add?

How do claims 2 through 7 narrow the enzyme profile?

Claims 2 through 7 create narrower fall-back positions around sequence identity and site-specific phosphorylation.

Claim	Added limitation
2	rhGAA is at least 95% identical to SEQ ID NO: 4, or corresponds to SEQ ID NO: 4 lacking the first 56 amino acids
3	At least 55% of molecules have a bis-M6P unit at N84
4	At least 70% of molecules are phosphorylated at N84
5	At least 40% have a mono-M6P unit at N177
6	At least 40% have a bis-M6P unit at N414
7	At least 25% have a mono-M6P unit at N414

Claim 2 is principally a sequence and processing limitation. It may cover mature or post-translationally processed rhGAA forms that are closely related to the disclosed sequence. Claims 3 through 7 increase the required glycan or phosphorylation levels and therefore narrow the claim set.

From an invalidity perspective, claims 3 through 7 may be more vulnerable to disputes over written description, enablement, analytical reproducibility, or anticipation if prior art disclosed similar site-specific phosphorylation profiles. From an enforcement perspective, they may be valuable because the thresholds can be tested using product characterization data.

What regimen does claim 8 protect?

Claim 8 specifies the principal treatment schedule:

rhGAA at about 20 mg/kg;
intravenous infusion over approximately four hours;
administration every two weeks;
miglustat administered one hour before the infusion;
fasting for at least two hours before and after oral miglustat.

This claim combines product characteristics with a detailed clinical protocol. The fasting requirement and one-hour pretreatment interval create potential non-infringement arguments if a commercial label changes the timing, does not require fasting, or uses a different infusion protocol.

What does claim 9 cover?

Claim 9 narrows the regimen to:

rhGAA at about 20 mg/kg intravenously; and
miglustat at about 260 mg orally.

This is a commercially significant claim because it corresponds to the principal adult dosing configuration associated with the Pombiliti and Opfolda treatment combination.[2]

What do claims 10 through 13 protect?

Claims 10 through 13 are kit claims. They shift the infringement focus from the act of treatment to the supplied product package and its instructions.

What is required by claim 10?

Claim 10 requires a kit containing:

a pharmaceutically acceptable miglustat dosage form for oral administration at about 260 mg or 130 mg;
a pharmaceutically acceptable rhGAA dosage form for intravenous administration at about 5 mg/kg to about 20 mg/kg;
instructions for administering both to a Pompe disease patient; and
the same CHO-cell, glycan-site, complex-glycan, and N84 bis-M6P limitations in claim 1.

Claim 10 could be asserted against a packaged combination product, co-branded treatment system, or distribution configuration that supplies both products and instructions. It is less dependent than method claims on whether a particular patient actually completed the regimen.

What do claims 11 and 13 add?

Claims 11 and 13 require instructions covering:

approximately 20 mg/kg rhGAA;
intravenous infusion over approximately four hours every two weeks;
oral miglustat before the rhGAA infusion;
a one-hour interval between miglustat and rhGAA; and
fasting for at least two hours before and after miglustat.

The text supplied for claim 11 states that the instructions administer rhGAA "one hour after" oral miglustat. That is consistent with the one-hour pretreatment sequence in claim 8. Any commercial analysis should compare the issued claim text with the certified patent file because instruction-based claims can turn on the precise wording and order of administration.

When does US Patent 11,278,601 expire?

US Patent 11,278,601 issued on March 29, 2022.[1] Its ordinary patent term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments under 35 U.S.C. §§ 154 and 156.[3]

Public patent records associate the patent family with a February 2017 priority period and an expected expiration in 2037, subject to the USPTO-calculated term. The practical exclusivity date should be taken from the USPTO Patent Examination Data System and the patent's term-adjustment calculation rather than inferred solely from the issue date.

Event	Date or status
Earliest family priority period	February 2017
Patent issued	March 29, 2022
Expected ordinary term endpoint	2037, subject to USPTO adjustment
FDA approval of Pombiliti/Opfolda combination	September 28, 2023
Orphan-drug exclusivity	Generally through September 28, 2030, if applicable to the approved products
Patent-based commercial barrier	Expected to extend beyond orphan exclusivity

Patent expiration and FDA regulatory exclusivity are separate. Orphan-drug exclusivity can block approval of the same drug for the same indication during its statutory period, while the patent can restrict making, using, selling, offering to sell, or importing the claimed combination after regulatory exclusivity ends.

What is the Orange Book status of US Patent 11,278,601?

Pombiliti is regulated as a biologic, while Opfolda is the associated miglustat product. The Orange Book generally does not operate as the primary patent listing system for biologic license applications. Patent listing analysis therefore requires separating:

the BLA for Pombiliti;
the NDA for Opfolda;
patent listings associated with the small-molecule component; and
biologic exclusivity and patent records maintained outside the conventional Orange Book framework.

Because US 11,278,601 claims a combination involving miglustat and rhGAA, it may have relevance to the Opfolda NDA's method-of-use patent listings even though the principal enzyme product is regulated under a BLA. A definitive Orange Book position should be based on the current FDA patent-listing record for the approved miglustat product, not solely on the patent's claims.[4]

Which companies are challenging the patent estate?

No publicly identified Paragraph IV litigation or final court judgment directed specifically to US 11,278,601 is established in the information supplied. Paragraph IV litigation would be most relevant to an ANDA seeking approval for miglustat with a patented Pompe disease use. Such a filing would not create a conventional generic pathway for the rhGAA biologic itself.

The more likely competitive threat is a 351(k) biosimilar or other follow-on biologic to the rhGAA component. A biosimilar applicant could challenge patents through:

a statutory patent dance under the Biologics Price Competition and Innovation Act;
declaratory-judgment litigation;
a non-infringement or invalidity defense;
a product design that changes glycan occupancy or host-cell production; or
a label strategy that omits the patented combination use, where legally viable.

A biosimilar challenge to the enzyme would not necessarily defeat claims directed to a kit containing miglustat, and a miglustat ANDA would not necessarily address the enzyme's composition or manufacturing patents.

How strong is the patent estate for Pombiliti and Opfolda?

US 11,278,601 has meaningful commercial strength because it combines the approved therapy's core components with product-specific molecular attributes. Its strength is highest against a product that is:

the same or substantially similar CHO-derived rhGAA;
used at 20 mg/kg every two weeks;
administered with 260 mg miglustat;
labeled with the one-hour pretreatment and fasting instructions; and
distributed as a combination kit.

Its main weaknesses are claim complexity and evidentiary burden. The patentee would need to establish the relevant enzyme characteristics, including site-specific M6P occupancy and total complex N-glycan percentages. Those attributes may not be apparent from a public label and may require discovery, regulatory filings, batch testing, or expert analysis.

Risk factor	Assessment
Combination regimen coverage	Strong for the approved regimen
Composition specificity	Strong but narrow
Dependence on analytical testing	High
Generic small-molecule exposure	Limited because the claims require rhGAA
Biosimilar exposure	Material, particularly for matching CHO-derived glycan profiles
Kit claim exposure	Strong if both products and instructions are packaged together
Design-around potential	Moderate through host cell, glycan profile, dosing, or labeling changes
Post-2030 commercial risk	Increases as orphan exclusivity ends, while patent protection may continue

What formulations and manufacturing processes remain protected?

The claims do not protect a conventional tablet formulation of miglustat alone. They protect miglustat as part of a specified treatment combination or kit. The rhGAA limitations are more important than excipient composition.

The patent's manufacturing relevance comes from the requirement that rhGAA molecules be produced in CHO cells. The claims also identify seven potential N-glycosylation sites and require defined M6P and complex-glycan characteristics. These limitations create process and characterization barriers because a competitor must control:

host-cell selection;
clone selection;
culture conditions;
glycan processing;
phosphorylation efficiency;
purification;
batch consistency; and
release testing.

A process that produces rhGAA with the same amino-acid sequence but materially different glycan occupancy could avoid literal infringement of some claims. It may still face other patents covering the sequence, enzyme production, glycan engineering, formulation, or Pompe treatment.

How does this patent compare with competing Pompe disease therapies?

Product	Active therapy	Sponsor	Regulatory category	Relevance to US 11,278,601
Pombiliti plus Opfolda	Cipaglucosidase alfa plus miglustat	Amicus Therapeutics	Biologic plus small molecule	Direct commercial target
Nexviazyme	Avalglucosidase alfa	Sanofi	Biologic	No miglustat requirement in the cited patent
Lumizyme/Myozyme	Alglucosidase alfa	Sanofi	Biologic	Different rhGAA product and regimen
Potential biosimilar	Follow-on rhGAA	Future entrants	351(k) pathway	Could face composition, method, and kit patents

US 11,278,601 is not a general patent on Pompe enzyme replacement therapy. It is differentiated by its required combination with miglustat and by the defined CHO-derived glycan profile. Competing products using a different rhGAA, such as avalglucosidase alfa or alglucosidase alfa, do not fall within the claims merely because they treat Pompe disease.

What generic launch risks exist?

A standalone miglustat generic would face limited exposure to this patent unless its labeling, packaging, or marketing induced use with the claimed rhGAA regimen. The larger barrier concerns a combined entrant seeking to reproduce the Pombiliti/Opfolda treatment system.

Potential launch scenarios include:

Post-orphan-exclusivity miglustat entry: A generic miglustat product launches after the relevant exclusivity period, but its label omits the patented Pompe combination use.
Biosimilar rhGAA entry: A follow-on enzyme launches with a non-infringing glycan profile or different manufacturing host.
Full combination challenge: An entrant challenges the patent and related family members through litigation or a negotiated license.
Authorized or licensed entry: A competitor obtains a license or commercial arrangement with the patent holder.
Label carve-out strategy: The entrant removes the patented use from labeling, subject to inducement and regulatory constraints.

The highest litigation risk exists for an entrant that copies the approved dosing sequence, supplies both products with coordinated instructions, and uses a CHO-derived enzyme meeting the claimed M6P thresholds.

What licensing deals and litigation affect the patent?

No licensing agreement or settlement specific to US 11,278,601 is identified in the supplied record. Amicus Therapeutics is the commercial company associated with the Pombiliti/Opfolda combination, and the patent's commercial value is tied to that treatment platform.

No final Paragraph IV judgment, consent judgment, or settlement specific to this patent is established here. Related patents in the same family or neighboring patent families may produce separate litigation exposure even if US 11,278,601 itself has not been litigated.

Key Takeaways

US 11,278,601 protects a Pompe disease treatment using oral miglustat with intravenous CHO-derived rhGAA.
The independent claims require specific doses, administration routes, glycan sites, complex-glycan content, and N84 bis-M6P occupancy.
Claims 8, 9, 11, and 13 closely track the commercial 20 mg/kg rhGAA plus 260 mg miglustat regimen.
The patent covers both treatment methods and combination kits.
The expected patent term extends into 2037, subject to USPTO patent-term adjustment.
Orphan-drug exclusivity is a separate barrier and generally runs for seven years from the applicable approval date.
A conventional generic miglustat would not inherently practice the claims because the claims require rhGAA.
The main competitive risk is a biosimilar or follow-on rhGAA product that matches the claimed CHO-derived glycan profile.
The principal design-around options are changing the production host, glycan profile, dosing schedule, administration sequence, or kit and labeling structure.
Patent enforcement would likely depend on confidential product characterization and evidence of induced or labeled use.

FAQs

Can a generic miglustat infringe US 11,278,601 without selling rhGAA?

Potentially, but not merely by selling miglustat. The claims require treatment or kit combinations involving the specified rhGAA. Liability would depend on the product's labeling, instructions, packaging, or conduct promoting the claimed combination.

Does the patent cover avalglucosidase alfa?

Not on the claim language supplied. The claims require rhGAA with specified sequence-related and glycan characteristics produced in CHO cells. Avalglucosidase alfa is a distinct recombinant enzyme product and would require a separate claim-by-claim comparison.

Can a biosimilar avoid the patent by using a different cell line?

A different host cell could avoid the literal CHO-cell limitation in the cited claims. It would not eliminate exposure to other patents covering the enzyme sequence, glycosylation, formulation, manufacturing process, or treatment method.

Is US 11,278,601 a composition-of-matter patent?

No. The independent claims supplied are method claims and kit claims. The enzyme characteristics are incorporated as limitations into those claims rather than claimed as an unrestricted standalone rhGAA composition.

Does FDA approval establish infringement?

No. FDA approval and patent infringement are separate issues. Regulatory approval may provide evidence concerning the labeled regimen, but infringement depends on the issued claim limitations and the accused product's actual composition, instructions, use, and commercial conduct.

References

United States Patent and Trademark Office. (2022). US Patent No. 11,278,601, methods of treating Pompe disease using recombinant human acid alpha-glucosidase and miglustat.
U.S. Food and Drug Administration. (2023). Pombiliti (cipaglucosidase alfa-atga) prescribing information and Opfolda (miglustat) prescribing information.
United States Code. (2024). 35 U.S.C. §§ 154 and 156: Patent term and patent term extension.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations and patent listing provisions.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amicus Therap Us	OPFOLDA	miglustat	CAPSULE;ORAL	215211-001	Sep 28, 2023		RX	Yes	Yes	11,278,601	⤷ Start Trial	Y			THE TREATMENT OF POMPE PATIENTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	107277	⤷ Start Trial
Australia	2016381832	⤷ Start Trial
Australia	2024200071	⤷ Start Trial
Australia	2026201393	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,278,601

Which drugs does patent 11,278,601 protect, and when does it expire?

Summary for Patent: 11,278,601